Latest

Learn how antibiotic-resistant UTI testing identifies ESBL, CRE, resistance genes, and antibiotic susceptibility, and how culture results guide treatment and follow-up.

Antibiotic-Resistant UTI Test: ESBL, CRE, Resistance Markers, and Culture Meaning

Learn what asymptomatic bacteriuria means, how a positive urine culture without UTI symptoms is interpreted, and when screening, treatment, or follow-up matters.

Asymptomatic Bacteriuria Test: Positive Culture Without Symptoms and When It Matters

Learn how bacteria in urine are interpreted using urinalysis, culture, colony count, symptoms, and sample quality, including when contamination or follow-up testing matters.

Bacteria in Urine Test: UTI, Contamination, Colony Count, and Culture Follow-Up

Learn how a catheter urine culture helps diagnose catheter-associated UTI, how samples are collected, and what colony counts, pyuria, resistance, and positive results mean.

Catheter Urine Culture Test: Catheter-Associated UTI and Culture Meaning

Learn how a chlamydia and gonorrhea urine NAAT works, how to collect first-catch urine, what positive or negative results mean, and when follow-up testing is needed.

Chlamydia and Gonorrhea Urine NAAT Test: STI Screening, Positive Result, and Meaning

Learn how to collect a clean-catch urine culture, reduce contamination, handle the sample correctly, and understand mixed flora, colony counts, repeat testing, and accurate results.

Clean-Catch Urine Culture Test: Sample Collection, Contamination, and Accurate Results

Diagnostics

Home Diagnostics Page 32

Understand CEBPA mutation testing in AML, including bZIP in-frame mutations, ELN favorable-risk classification, prognosis, germline CEBPA, and how results affect treatment planning.

CEBPA Mutation Test: AML Prognosis, Risk Stratification, Mutation Status, and Meaning

Understand CHEK2 mutation testing, breast, colon, and prostate cancer risk, pathogenic variants versus VUS results, family inheritance, cascade testing, and screening implications.

CHEK2 Mutation Test: Breast, Colon, Prostate Cancer Risk, Variant Meaning, and...

Understand DDIT3 fusion testing for myxoid liposarcoma, including FUS::DDIT3, EWSR1::DDIT3, FISH and RNA testing, positive and negative results, and diagnostic meaning.

DDIT3 Fusion Test: Myxoid Liposarcoma, Gene Fusion, and Molecular Diagnosis

Understand EGFR mutation testing in lung cancer, including exon 19 deletions, L858R, T790M, exon 20 insertions, liquid biopsy, resistance, and treatment meaning.

EGFR Mutation Test: Exon 19, L858R, T790M, Mutation Status, and Lung...

Understand EPCAM deletion testing for Lynch syndrome, including MSH2 silencing, colorectal cancer risk, MMR and MSI findings, family inheritance, and surveillance implications.

EPCAM Deletion Test: Lynch Syndrome, Colon Cancer Risk, MSH2 Silencing, and...

Learn what an ESR1 mutation test means in breast cancer, how ctDNA testing detects hormone resistance, how results affect treatment, and how ESR1 relates to recurrence.

ESR1 Mutation Test: Breast Cancer, Hormone Resistance Marker, Mutation Status, and...

EWSR1 Fusion Test Sarcoma, Ewing Tumor, Gene Fusion, and Tumor Classification

EWSR1 Fusion Test: Sarcoma, Ewing Tumor, Gene Fusion, and Tumor Classification

Learn what an EZH2 mutation test means in follicular lymphoma, how positive and negative results are interpreted, and how the 2026 tazemetostat withdrawal changes treatment relevance.

EZH2 Mutation Test: Lymphoma, Mutation Status, Prognosis, and Molecular Meaning

Learn what an FGFR3 mutation test means in bladder cancer, which FGFR3 alterations are actionable, how tissue and ctDNA testing work, and how results can guide treatment.

FGFR3 Mutation Test: Bladder Cancer, Mutation Status, and Molecular Meaning

Learn what a FUS fusion test detects in sarcoma, what FUS::DDIT3 and FUS::CREB3L2 mean, how testing is performed, and how results guide tumor classification.

FUS Fusion Test: Sarcoma Gene Fusion, Tumor Classification, and Molecular Result

Learn how a gene fusion panel detects cancer rearrangements, why RNA-based NGS is useful, what positive and negative results mean, and how fusions can guide tumor classification and targeted therapy.

Gene Fusion Panel Test: Cancer Fusions, Rearrangement Markers, and Molecular Tumor...

Learn what a HER2/ERBB2 mutation test means in lung, breast, and gastric cancer, how mutations differ from HER2 amplification or IHC, and how results can guide targeted treatment.

HER2/ERBB2 Mutation Test: Breast, Gastric, Lung Cancer, Mutation Status, and HER2...

Learn what an HRD test measures in ovarian cancer, how genomic instability scores and BRCA status are interpreted, what HRD-positive means, and how results can inform PARP inhibitor treatment decisions.

Homologous Recombination Deficiency (HRD) Test: DNA Repair Deficiency, Ovarian Cancer, and...

Learn what an HRAS mutation test means in head and neck cancer and thyroid disease, how hotspot and VAF results are interpreted, and why a positive HRAS result has different implications by tumor type.

HRAS Mutation Test: Head and Neck Cancer, Thyroid Cancer, Mutation Status,...

Learn what an IDH1 mutation test means in glioma, AML, and cholangiocarcinoma, how R132 mutations are detected, and how positive results can affect diagnosis and targeted treatment.

IDH1 Mutation Test: Glioma, Leukemia, Cholangiocarcinoma, Mutation Status, and Meaning

Understand what an IDH2 mutation test means in AML, glioma, and cholangiocarcinoma, including positive and negative results, treatment relevance, testing methods, and important limitations.

IDH2 Mutation Test: Leukemia, Glioma, Cholangiocarcinoma, Mutation Status, and Meaning

1...313233...137 Page 32 of 137